ES2091438T3 - Anticuerpos recombinantes especificos para un receptor del factor de crecimiento. - Google Patents

Anticuerpos recombinantes especificos para un receptor del factor de crecimiento.

Info

Publication number
ES2091438T3
ES2091438T3 ES92810056T ES92810056T ES2091438T3 ES 2091438 T3 ES2091438 T3 ES 2091438T3 ES 92810056 T ES92810056 T ES 92810056T ES 92810056 T ES92810056 T ES 92810056T ES 2091438 T3 ES2091438 T3 ES 2091438T3
Authority
ES
Spain
Prior art keywords
chain variable
variable domain
dna
recombinant antibodies
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92810056T
Other languages
English (en)
Inventor
Winfried Stephan Dr Wels
Nancy E Dr Hynes
Ina-Maria Harwerth
Bernd Dr Groner
Norman Dr Hardman
Markus Zwickl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2091438T3 publication Critical patent/ES2091438T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS RECOMBINANTES DIRIGIDOS AL DOMINIO EXTRACELULAR DEL RECEPTOR DE FACTOR DE CRECIMIENTO HUMANO C-ERBB-2 QUE CONSTA DE UN DOMINIO VARIABLE DE CADENA LIGERA Y UN DOMINIO VARIABLE DE CADENA PESADA DE UN ANTICUERPO MONOCLONAL, ANTICUERPOS MONOCLONALES DIRIGIDOS A LOS C-ERBB-2 MISMO, UN METODO DE ELABORACION DE TALES ANTICUERPOS RECOMBINANTES Y DE LOS ANTICUERPOS MONOCLONALES MENCIONADOS, CELULAS HIBRIDOMA QUE SEGREGAN LOS ANTICUERPOS MONOCLONALES MENCIONADOS, UN METODO DE ELABORACION DE LAS CELULAS HIBRIDOMAS MENCIONADAS, CODIFICACION DE ADN PARA EL DOMINIO VARIABLE DE CADENA PESADA, PARA EL DOMINIO VARIABLE DE CADENA LIGERA Y PARA EL ANTICUERPO RECOMBINANTE, UN METODO DE ELABORACION DEL ADN MENCIONADO, VECTORES HIBRIDOS ADECUADOS PARA LA EXPRESION DEL ADN MENCIONADO, CELULAS HUESPEDES TRANSFORMADAS CON EL ADN MENCIONADO, Y EL USO DE LOS ANTICUERPOS RECOMBINANTES MENCIONADOS Y DE LOS ANTICUERPOS MONOCLONALES MENCIONADOS EN EL DIAGNOSTICO Y TRATAMIENTO DE TUMORES.
ES92810056T 1991-02-05 1992-01-27 Anticuerpos recombinantes especificos para un receptor del factor de crecimiento. Expired - Lifetime ES2091438T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91810079 1991-02-05

Publications (1)

Publication Number Publication Date
ES2091438T3 true ES2091438T3 (es) 1996-11-01

Family

ID=8208816

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92810056T Expired - Lifetime ES2091438T3 (es) 1991-02-05 1992-01-27 Anticuerpos recombinantes especificos para un receptor del factor de crecimiento.

Country Status (10)

Country Link
EP (1) EP0502812B1 (es)
JP (1) JP3415171B2 (es)
AT (1) ATE141329T1 (es)
AU (1) AU662311B2 (es)
CA (1) CA2060544C (es)
DE (1) DE69212671T2 (es)
DK (1) DK0502812T3 (es)
ES (1) ES2091438T3 (es)
GR (1) GR3020809T3 (es)
IE (1) IE72959B1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
WO1994020636A1 (en) * 1993-03-09 1994-09-15 Abbott Laboratories Genetically engineered enzymes and their conjugates for diagnostic assays
IT1264083B1 (it) * 1993-12-10 1996-09-10 Enea Ente Nuove Tec Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
IL126303A (en) * 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
HK1047236A1 (zh) 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
EP1521776A2 (en) 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
WO2006083355A2 (en) 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
RU2014126098A (ru) 2011-11-30 2016-01-27 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2022161314A1 (zh) 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
AU3693389A (en) 1988-05-23 1989-12-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cloned gene for expression of antibodies reacting with human ovarian cancer
JP2761543B2 (ja) 1988-08-17 1998-06-04 味の素株式会社 ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ
EP0967277A3 (en) * 1988-09-06 2003-10-15 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
EP0531472B1 (en) * 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
DE69228300T2 (de) * 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung

Also Published As

Publication number Publication date
AU662311B2 (en) 1995-08-31
CA2060544C (en) 2002-12-03
DE69212671T2 (de) 1997-03-13
ATE141329T1 (de) 1996-08-15
AU1042192A (en) 1992-08-13
JP3415171B2 (ja) 2003-06-09
EP0502812A1 (en) 1992-09-09
GR3020809T3 (en) 1996-11-30
CA2060544A1 (en) 1992-08-06
JPH05192183A (ja) 1993-08-03
DE69212671D1 (de) 1996-09-19
IE72959B1 (en) 1997-05-07
IE920361A1 (en) 1992-08-12
DK0502812T3 (da) 1996-09-02
EP0502812B1 (en) 1996-08-14

Similar Documents

Publication Publication Date Title
ES2091438T3 (es) Anticuerpos recombinantes especificos para un receptor del factor de crecimiento.
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
HU9402823D0 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
MX9201016A (es) Anticuerpos monoclonales humanizados y quimericos
DE69638355D1 (de) Anti-CD3-Antikörper zur Verwendung zur Induzierung von Immunsuppression
NL300335I2 (nl) Menselijke monoklonale antilichamen tegen epidermale groeifactorreceptor
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
CU22545A1 (es) Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
CY1107163T1 (el) Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502812

Country of ref document: ES